Drugs that contain Paliperidone Palmitate
1. Invega Hafyera patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11324751 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(17 years from now) | |
| US11304951 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(17 years from now) | |
| US11666697 | JANSSEN PHARMS | Methods for ensuring resuspension of paliperidone palmitate formulations |
Nov, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 30, 2024 |
| New Product(NP) | May 18, 2018 |
Market Authorisation Date: 30 August, 2021
Treatment: Treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose; Reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks ...
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA HAFYERA family patents
2. Invega Sustenna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5254556 | JANSSEN PHARMS | 3-piperidinyl-1,2-benzisoxazoles |
Oct, 2013
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5352459 | JANSSEN PHARMS | Use of purified surface modifiers to prevent particle aggregation during sterilization |
Dec, 2012
(11 years ago) | |
|
US5352459 (Pediatric) | JANSSEN PHARMS | Use of purified surface modifiers to prevent particle aggregation during sterilization |
Jun, 2013
(10 years ago) | |
|
US5254556 (Pediatric) | JANSSEN PHARMS | 3-piperidinyl-1,2-benzisoxazoles |
Apr, 2014
(10 years ago) | |
| US6077843 | JANSSEN PHARMS | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
May, 2017
(6 years ago) | |
|
US6077843 (Pediatric) | JANSSEN PHARMS | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
Nov, 2017
(6 years ago) | |
| US6555544 | JANSSEN PHARMS | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters |
Nov, 2018
(5 years ago) | |
|
US6555544 (Pediatric) | JANSSEN PHARMS | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters |
May, 2019
(4 years ago) | |
| US9439906 | JANSSEN PHARMS | Dosing regimen associated with long acting injectable paliperidone esters |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2011 |
| New Indication(I-698) | Nov 12, 2017 |
| M(M-215) | Dec 20, 2020 |
| New Dosage Form(NDF) | Jul 31, 2012 |
| Pediatric Exclusivity(PED) | Jan 31, 2013 |
| M(M-119) | Aug 29, 2015 |
NCE-1 date: 01 February, 2012
Market Authorisation Date: 31 July, 2009
Treatment: Treatment of schizophrenia; Dosing regimen for the treatment of schizoaffective disorder in adults as a monotherapy and as an adjunct to mood stabilizers or antidepressants by administering two loadin...
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA SUSTENNA family patents
3. Invega Trinza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6077843 | JANSSEN PHARMS | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
May, 2017
(6 years ago) | |
|
US6077843 (Pediatric) | JANSSEN PHARMS | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
Nov, 2017
(6 years ago) | |
| US10143693 | JANSSEN PHARMS | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
Apr, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 30, 2024 |
| New Product(NP) | May 18, 2018 |
Market Authorisation Date: 30 August, 2021
Treatment: Treatment of schizophrenia; Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA TRINZA family patents